Searched for
DRL SHARE PRICE
Dr. Reddy’s shares rise over 1% on strategic collaboration with Alvotech for Keytruda BiosimilarDr. Reddy’s Laboratories has partnered with global biotech firm Alvotech to co-develop and commercialize a biosimilar of Keytruda (pembroli...- Dr. Reddy’s Laboratories shares in focus on denial of workforce reductionDr. Reddy’s Laboratories shares: In a regulatory filing, the pharmaceutical giant addressed a Business Standard article dated April 13, whi...
- Dr Reddy's shares rally 4% as Nuvama upgrades rating to buyDr. Reddy’s Laboratories shares rose 4% after Nuvama upgraded its rating to 'buy,' citing proactive strategies to mitigate the impact of Re...
- Here's a look at highest-paid top brass from pharma industryThis looks at the total remuneration of senior employees in the pharma space. Remuneration here is the director's salary inclusive of benef...
- Dr Reddy's tumbles 7% post Q4 results! Here's what brokerages recommendDr Reddy's Laboratories reported an 890% YoY surge in March quarter profit at Rs 960.1 crore but shares tumbled nearly 7% to Rs 4,545 in Th...
- Trader's Guide: 2 laregcap pharma stocks that can rise up to 5%This pharmaceutical stock is on the verge of a breakout from the technical price pattern of a symmetrical triangle. A close near the breako...
- Dr Reddy's Labs Q4 Results: Consolidated profit tanks 76% YoY to Rs 88 croreThe profit figure was sharply lower compared with an ET Now analysts’ poll projection of Rs 560 crore.
- DRL Q3 Results: Drugmaker posts 25 times rise in PAT at Rs 709 cr, in line with estimatesThe revenue from operations came in at Rs 5,103 crore, up 8.3 per cent against Rs 4,711 crore in the corresponding quarter last year.
- DRL Q3 Results Preview: Profit may grow 25% YoY; margin likely to fallEdelweiss sess profit rising 26.5 per cent YoY to Rs 780 crore. It sees sales rising 12.2 per cent YoY to Rs 5,531 crore. The brokerage see...
- Dr Reddy’s Q2 results: Consolidated PAT rises 30% YoY, beats estimateThe drugmaker reported an 18 per cent on-year rise in consolidated revenues to Rs. 5,763 crore for the reported quarter, which also beat St...
- Neutral on Dr. Reddy's Laboratories, target price Rs 5200: Motilal OswalDr. Reddy's Laboratories Ltd., incorporated in the year 1984, is a Large Cap company (having a market cap of Rs 80574.04 Crore) operating i...
- Dr Reddy's lines up Rs 1,000 crore capex for current fiscal yearThe Hyderabad based firm invested about Rs 1,000 crore in the 2020-21 fiscal year.
- Dr Reddy's strong product pipeline and other factors that make it stock pick of the weekDRL continues to generate free cash flows (FCFs) due to strongholds in some legacy drugs. Its lower valuation compared to its peers and str...
- Stocks in the news: Dr Reddy's, Bajaj Auto, IOC, UPL, LVB and Blue StarT Rowe Price International has bought shares of air-conditioner maker Blue Star.
- Dr Reddy’s Labs climbs 4% on sale of API unitDRL did not disclose the deal amount.
- DRL takes a hit of 10% on US court orderIndivior sees a $25 million dent on its revenues due to the product of Dr Reddy's.
- Brokerages raise price target on Dr Reddy's to as high as Rs 2,720 on FDA nodBrokerages see the FDA approval to Dr Reddy’s Laboratories (DRL) for generic Vidaza as a positive for the company.
- Dr Reddy's Laboratories acquires 93% shares of OctoPlusDr Reddy's Laboratories has so far managed to get nearly 93% shares of Netherlands-based speciality pharmaceutical company OctoPlus NV.
- Analyst's Pick: Dr Reddy's LaboratoriesCitigroup recommends 'Hold' rating on Dr Reddy’s Laboratories with a target price of Rs 547.
- Dr Reddy's trims non-US operationsThe company is trimming operations in many CIS countries, in the Middle East and Africa.
Load More
